0OT Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high-80% to low-90% gross margins indicate attractive product-level economics. This provides a durable foundation for scaling DEXTENZA and future products, although operating expenses and development spending have so far prevented profitability.
Manageable LeverageImproved debt-to-equity and a sizable equity and asset base provide greater financial flexibility than in earlier periods. This can support ongoing operations and development investment, although persistent losses remain a constraint.
Commercial Platform And Leadership ContinuityCommercializing DEXTENZA while advancing a sustained-release ophthalmic platform gives Ocular Therapeutix an established product and potential pipeline leverage. The confirmed CFO appointment also supports continuity in financial leadership.
Bears Say
Weak Revenue TractionRevenue has not yet demonstrated durable acceleration: annual sales declined materially and trailing-twelve-month growth remains modest. Limited top-line expansion constrains operating leverage and reduces the company’s ability to absorb substantial fixed costs.
Persistent Losses And Cash BurnLarge, worsening operating losses and consistently negative operating and free cash flow show that the business is not self-funding. Continued development and commercialization may therefore require additional capital if cash outflows persist.
Equity Dilution RiskAuthorizing 10 million additional equity-plan shares increases the potential for dilution over time. While equity awards may support retention and leadership alignment, expanded share issuance can reduce existing holders’ ownership in a capital-intensive biotech.
Ocular Therapeutix News
0OT FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Currently, no data Available
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is CHF1.90B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Nov 09, 2026 which is in 75 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Aug 03, 2026. The company reported -CHF0.284 earnings per share for the quarter, beating the consensus estimate of -CHF0.32 by CHF0.037.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.3.
How many shares outstanding does Ocular Therapeutix have?
Currently, no data Available
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -CHF0.284 in its last earnings report, beating expectations of -CHF0.32. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in CH:0OT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF20.67 (― Upside)
CHF20.67 (― Upside)
Blogger Sentiment
Bullish
CH:0OT Sentiment 67%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth CHF288.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.74%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
0OT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive clinical narrative: a landmark superiority result (p=0.0006), clear durability and anatomic benefits, an encouraging safety profile, robust enrollment and accelerated timelines for SOL-R, initiation of a long-term extension (SOL-X), and a solid cash position. The primary negatives were regulatory/timing uncertainty, the explicit note that cash runway excludes full commercialization costs, and limited disclosure of some granular metrics. On balance, the highlights substantially outweigh the lowlights.View all CH:0OT earnings summaries0OT Stock 12 Month Forecast
Average Price Target
―EyePoint Pharmaceuticals
―
RegenXBio
―
Tarsus Pharmaceuticals
―
Oculis Holding
―
Aura Biosciences Inc
―